Equity Research Report: Poly Medicure Ltd (PolyMed)
Date: February 7, 2026
Market Price (CMP): ₹1,386 (approx)
Market Cap: ~₹14,100 Cr
Sector: Medical Devices (Healthcare)
1️⃣ Business Model & Work
Company Overview:
Poly Medicure (PolyMed) India ki leading Medical Devices manufacturer hai. Ye company dawaiyan nahi banati, balki un devices ko banati hai jinke through dawai body me deliver ki jaati hai (Ex: Sui, Nali, Katheter). Inke paas 200+ patents hain aur ye 125+ countries me products export karte hain.
Revenue Sources (Approximate Split):
- Exports: ~70% (Europe aur Rest of World major markets hain).
- Domestic (India): ~30% (Hospital chains aur Nursing homes main clients hain).
Key Product Segments:
- Infusion Therapy (~60-65% Revenue): IV Cannula (World leader), Syringes. Ye “Bread and Butter” business hai.
- Renal Care (High Growth): Dialysis machines aur kits.
- Vascular Access & Blood Management: Blood bags, catheters.
- New Segment: Cardiology (Stents) – Ye future growth driver hai.
Competitive Advantage:
- Cost Leadership: India me manufacturing cost low hai, jisse ye global players (B. Braun, BD) se sasta bech paate hain.
- Backward Integration: Ye apne molds aur tools khud banate hain, jo quality control aur cost saving me help karta hai.
2️⃣ Industry & Sector Analysis
Status: Secular & High Growth
Medical Devices sector India me “Sunrise Sector” hai. Current market size chhota hai lekin growth potential pharma se bhi tez hai.
Growth Drivers:
- PLI Scheme: Government of India ne domestic production badhane ke liye PLI (Production Linked Incentive) scheme launch ki thi, jiska PolyMed ek bada beneficiary hai.
- China + 1: Global hospitals supply chain risk kam karne ke liye China ke alawa India se sourcing badha rahe hain.
- Chronic Diseases: Kidney aur Heart diseases badhne se Dialysis aur Stents ki demand badh rahi hai.
Major Competitors:
Global Giants (Becton Dickinson, B. Braun) aur Domestic players like La Med Healthcare (Unlisted). Listed space me direct competitor kam hain.
3️⃣ Latest Financial Performance (Verified Data)
Data Source: Exchange Filings & Screener (Consolidated)
Current Date Context: Feb 7, 2026 (Q3 FY26 Results Declared)
| Metric | FY 2023 | FY 2024 | FY 2025 (Actual) | Q3 FY26 (Latest Qtr) |
| Revenue | ₹1,068 Cr | ₹1,307 Cr | ₹1,670 Cr | ₹494 Cr (+16% YoY) |
| Operating Profit (EBITDA) | ₹266 Cr | ₹351 Cr | ₹453 Cr | ₹119 Cr (+3% YoY) |
| OP Margin (%) | 25% | 27% | 27% | 24.2% (Compressed) |
| Net Profit (PAT) | ₹179 Cr | ₹252 Cr | ₹339 Cr | ₹71 Cr (-17% YoY) |
| EPS (₹) | 18.66 | 26.23 | 34.10 | 7.40 (Quarterly) |
Recent Performance Analysis (Q3 FY26):
- Topline Growth: Sales me ~16% ki achi growth hai, jo dikhata hai demand strong hai.
- Margin Pressure: Operating Margins 27% se girkar 24.2% par aa gaye hain. Reason: Freight cost aur nayi labour policies ka impact.
- Profit Dip: PAT me ~17% ki girawat hai due to one-time exceptional costs aur acquisition expenses. Ye temporary lag raha hai.
Key Ratios:
- ROE: ~16-18% (Healthy).
- ROCE: ~20% (Efficient Capital Allocation).
- Debt/Equity: 0.06 (Almost Debt Free).
- Cash Flow: Company free cash flow positive hai.
4️⃣ Management & Shareholding (Dec 2025)
Shareholding Pattern:
| Category | Holding (%) | Trend |
| Promoters | 62.42% | ⏸️ Stable (Baid Family, very committed) |
| FIIs | 9.40% | 🔻 Slight Decrease recently |
| DIIs (Mutual Funds) | ~13-14% | 🔼 Increasing consistently |
| Public | ~14% | – |
- Management Quality: Himanshu Baid (MD) ek visionary leader maane jaate hain. Unhone company ko sirf ek commodity player se “Technology Player” me convert kiya hai.
- Governance: Clean track record. Koi major red flags ya pledging issues nahi hain.
5️⃣ Valuation (Latest Market Data)
Current Valuation:
- PE Ratio (TTM): ~40x – 44x
- 5-Year Avg PE: ~55x
- Price to Book (PB): ~5.3x
Peer Comparison:
Direct listed peers kam hain, lekin healthcare valuations ke hisab se:
- Poly Medicure: ~42x PE (Growth factor ki wajah se premium milta hai).
- Tarson Products (Labware): ~35x PE.
Interpretation:
Stock historically premium valuation par trade karta hai (50x+ PE). Recent price correction (jo aaj ~7% gira hai) aur earnings miss ki wajah se valuation thoda cool-off hua hai. Ye “Expensive but High Quality” category me aata hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Renal & Cardiology Expansion:Company ab simple IV Cannula se move karke Dialysis Machines aur Heart Stents bana rahi hai. In products me margins 30%+ hote hain.
- US Market Entry:PolyMed historically US market me weak tha (regulatory reasons se). Ab naye FDA approvals ke saath ye US market me aggressively enter kar rahe hain, jo revenue 2x kar sakta hai.
- Capacity Expansion:Jaipur aur Faridabad me naye plants live ho chuke hain ya hone wale hain. Jaise hi ye full capacity par chalenge, revenue jump karega.
7️⃣ Present Situation (Current Outlook)
- Current Phase: “Correction & Consolidation”.Q3 FY26 ke soft results (profit girna) ki wajah se stock me aaj sharp selling (approx 7% down) dekhi gayi hai. Market high expectations lekar chal raha tha jo miss hui hain.
- Short-term: Weakness reh sakti hai jab tak margins wapas 26-27% range me nahi aate.
- Long-term: Structural story intact hai. Demand me kami nahi hai, sirf operational costs badhe hain jo pass-on kiye ja sakte hain.
8️⃣ Risk & Red Flags
- Raw Material Volatility: Inka main raw material Plastic Granules/Polymers hai, jo Crude Oil prices se link hota hai. Oil prices badhne par margin pressure aata hai.
- Export Dependence: 70% revenue bahar se aata hai. Europe me recession ya Red Sea jaise shipping issues inke freight cost ko drastically badha dete hain (jo is quarter me hua).
- Regulatory Risk: Medical devices highly regulated hote hain. Ek bhi quality failure ban ya recall ka reason ban sakta hai.
9️⃣ Final Verdict
- Summary: Poly Medicure ek High-Growth, Debt-Free company hai jo Medical Devices sector me market leader hai. Recent results me profit drop temporary operational issues ki wajah se hai, structural problem nahi hai.
- Long-term Investor: BUY ON DIPS. Current fall (approx ₹1380 level) ek acha accumulation zone ban sakta hai. 3-5 saal ka view rakhne walon ke liye wealth creator hai.
- Conservative Investor: Thoda wait karein. Valuation abhi bhi sasta nahi hai (40x PE).
- Aggressive Investor: Current levels par 30% quantity buy karein, aur girne par add karein.
Actionable Step:
Stock aaj news/result ke reaction me gira hai. Agar aapka horizon 3+ saal hai, to ise SIP mode me khareedna shuru karein. Immediate bounce ki umeed na karein, agle 1-2 quarter consolidation (time correction) ho sakta hai.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.